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OBJECTIVES This study was designed to evaluate whether rapid endothelialization of stainless steel stents
with a functional endothelium prevents stent thrombosis and reduces the restenotic process.
BACKGROUND A “pro-healing” approach for prevention of post-stenting restenosis is theoretically favored
over the use of cytotoxic or cytostatic local pharmacologic therapies. It is believed that the
central role of the vascular endothelium is to maintain quiescence of the underlying media and
adventitia.
METHODS Sixteen patients with de novo coronary artery disease were successfully treated with
implantation of endothelial progenitor cell (EPC) capture stents.
RESULTS Complete procedural and angiographic success was achieved in all 16 patients. The
nine-month composite major adverse cardiac and cerebrovascular events (MACCE) rate was
6.3% as a result of a symptom-driven target vessel revascularization in a single patient. There
were no other MACCE despite only one month of clopidogrel treatment. At six-month
follow-up, mean angiographic late luminal loss was 0.63  0.52 mm, and percent stent
volume obstruction by intravascular ultrasound analysis was 27.2  20.9%.
CONCLUSIONS This first human clinical investigation of this technology demonstrates that the EPC capture
coronary stent is safe and feasible for the treatment of de novo coronary artery disease. Further
developments in this technology are warranted to evaluate the efficacy of this device for the
treatment of coronary artery disease. (J Am Coll Cardiol 2005;45:1574–9) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.048American College of Cardiology Foundation
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She emergence of drug-eluting stents has dramatically
educed the incidence of in-stent restenosis (1,2). This
herapy interferes with the natural healing response by
reventing or significantly delaying the formation of a
unctional endothelial lining over the stent (3).
Recently, the existence of circulating endothelial progen-
tor cells (EPCs) has been identified as a key factor for
e-endothelialization (4). The early establishment of a
unctional endothelial layer after vascular injury has been
hown to assist in the prevention of neointimal proliferation
nd thrombus formation (5,6). The EPC capture stents
ave been developed using immobilized antibodies targeted
t EPC surface antigens. The HEALING-FIM (Healthy
ndothelial Accelerated Lining Inhibits Neointimal
rowth-First In Man) registry is the first clinical investi-
ation using this technology.
From the *Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands;
OrbusNeich, Fort Lauderdale, Florida; and ‡Terrence Donnelly Heart Centre, St.
ichael’s Hospital, University of Toronto, Toronto, Canada. This study was
upported by OrbusNeich, Fort Lauderdale, Florida. Mr. Davis and Dr. Rowland are
ull-time employees of OrbusNeich, and Dr. Kutryk is a consultant of Orbus Medical
echnologies.s
Manuscript received December 9, 2004; revised manuscript received January 22,
005, accepted January 25, 2005.ETHODS
atient selection. The HEALING-FIM registry is a
ingle-center, prospective, non-randomized registry trial.
atients were eligible if they were between ages 18 and 85
ears and had a diagnosis of stable or unstable angina or
ilent ischemia. Additional eligibility criteria were the pres-
nce of a single primary target lesion in a native coronary
rtery that was 2.5 to 3.5 mm in diameter that could be
overed by a single trial stent (13 mm or 18 mm length), a
tenosis of 51% to 99% of the luminal diameter as estimated
isually, and a flow rate of grade 1 or higher according to the
lassification of the Thrombolysis In Myocardial Infarction
TIMI) trial. Patients were not eligible for enrollment if
hey had an evolving myocardial infarction; stenosis of the
eft main coronary artery; a lesion located at an ostial
ocation; a calcified lesion that could not be completely
ilated before stenting; angiographically visible thrombus
ithin the target lesion; a left ventricular ejection fraction of
30%; or an intolerance of aspirin, clopidogrel, ticlopidine,
eparin, stainless steel, or contrast material. The trial was
eviewed and approved by the ethics review committee, and
ritten informed consent was obtained from all patients.
tudy device: EPC capture stent. The EPC antibody
urface consists of a covalently coupled polysaccharide
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May 17, 2005:1574–9 First Human Experience of EPC Capture Stentntermediate coating with murine monoclonal anti-human
D34 antibodies, attached to a stainless steel stent (R stent,
rbusNeich, Fort Lauderdale, Florida) (Fig. 1). This anti-
ody specifically targets CD34 cells (endothelial pro-
enitor cells are CD34 positive) in the vascular circula-
ion. This device was supplied in aqueous sodium azide
olution as a preservative to maintain bioactivity and
equired hand crimping by the operator onto a percuta-
eous transluminal coronary angioplasty balloon catheter
efore implantation.
tudy procedures. Lesions were treated according to local
tandard interventional techniques. Specifically, the decision
o predilate or direct stent was at the investigator’s discre-
ion, and post-dilation was performed as required to ensure
hat the residual stenosis was 20% by visual assessment,
ith a TIMI flow grade rate 3. In case of a dissection or
Abbreviations and Acronyms
EPC  endothelial progenitor cell
HAMA  human antimurine antibody
HEALING-FIM  Healthy Endothelial Accelerated
Lining Inhibits Neointimal
Growth-First In Man
IVUS  intravascular ultrasound
MACCE  major adverse cardiac and
cerebrovascular events
MI  myocardial infarction
SMC  smooth muscle cell
TIMI  Thrombolysis In Myocardial
InfarctionFigure 1. Endothelial progenitor cell (Encomplete coverage of the lesion, implantation of addi-
ional EPC capture R stents was permitted.
Intravenous boluses of heparin were administered to
aintain an activated clotting time 300 s during the
mplantation. Treatment with aspirin, at a dose of at least 80
g/day, was initiated at least 12 h before the procedure and
ontinued for one month. In addition, a loading dose of 300
g of clopidogrel was administered before the procedure,
ollowed by 75 mg daily for 28 days. Glycoprotein IIb/IIIa
nhibitors were used at the operator’s discretion. Angio-
raphic success was defined as the successful implantation of
he study device, with a stenosis of 20% of the vessel
iameter with TIMI flow grade 3.
ollow-up. All patients were scheduled for a clinical
ollow-up at one, six, and nine months following the
mplantation procedure to assess the anginal status and
he occurrence of major adverse cardiac and cerebrovas-
ular events (MACCE). An electrocardiogram was ob-
ained at each visit, and an angiographic and intravascular
ltrasound (IVUS) study was performed at a mean of 185
14 days.
uantitative angiographic and IVUS analysis. Coronary
ngiograms were obtained in multiple views after an intra-
oronary injection of nitrates. Offline quantitative analyses
f preprocedural, postprocedural, and six-month follow-up
ngiographic data were performed. Restenosis was defined
s a reduction of 50% or more of the luminal diameter. Late
uminal loss was defined as the difference between the
inimal luminal diameter after procedure and at six
onths. The target lesion was defined as the stentedPC) capture coating technology.
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tented segment.
Intravascular ultrasound was performed with an auto-
ated pullback at 0.5 mm/s to examine the target lesion at
ostprocedure and six-month follow-up. Lumen, stent, and
xternal elastic membrane contours were detected with the
se of CUARD QCU analysis software (CUARD BV,
ijk Bij Duurstede, the Netherlands), applying a three-
imensional reconstruction as described elsewhere (7).
tudy end points. The primary safety end point of this
tudy was the absence of stent thrombosis up to six months.
he second end point was a composite of MACCE, defined
s cardiac death, stroke, Q-wave or non–Q-wave myocardial
nfarction (MI), and target vessel revascularization. Stroke
as defined as a focal neurologic deficit resulting from a
ascular cause involving the central nervous system. Q-wave
I was defined as development of new abnormal Q waves
ot present on the patient’s baseline. Non–Q-wave MI was
efined as a creatine kinase of more than twice the upper
imit of normal with an abnormal level of the MB isoen-
yme of creatine kinase. The efficacy end point was late
uminal loss as determined by quantitative coronary angiog-
aphy and % stent volume obstruction by IVUS at six
onths. Stent thrombosis was angiographically docu-
ented as a complete occlusion (TIMI flow grade 0 or 1) or
flow-limiting thrombus (TIMI flow grade 1 or 2) of a
reviously successfully treated artery.
etection of human antimurine antibody (HAMA).
uman antimurine antibody testing was not added to the
tudy until several patients had already returned for follow-
p. Testing with baseline data was conducted on 4 of 16
atients. The HAMA was determined by a commercially
vailable enzyme-linked immunosorbent assay kit (ME-
AC, Hamburg, Germany) (8). A positive assay was
efined as 10 ng/ml. Significant levels of HAMA were
efined as 150 ng/ml.
istology. One specimen was retrieved by directional
therectomy (Flexi-cut, Guidant Europe SA, Diegem, Bel-
ium), fixed in 4% buffered formaldehyde with metal stent
ragments removed and embedded in paraffin.
Sections were stained with hematoxylin eosin and an
lastin stain (Resorcin Fuchsin) for general assessment of the
issue. Cellular characterization was performed with immu-
ocytochemistry, using antibodies against smooth muscle
specific alpha-actin), leukocytes (CD45), macrophages
mac 387), proliferation cells (Mib 1), and EPC (CD34).
ll antibodies except anti-CD34 were obtained from
AKO (DakoCytomation, Produktionsvej, Denmark).
tatistical analysis. Because of the size of the patient
opulation in this nonrandomized registry, no formal sta-
istical analysis was conducted to determine the efficacy of
he device. Continuous variables are expressed as mean 
D. Comparisons between postprocedure and six-month
ollow-up values were performed with a two-tailed paired t
est. A p value0.05 was considered statistically significant. mESULTS
aseline characteristics and procedural outcome. Over-
ll, 16 patients were enrolled in the HEALING-FIM
egistry between May and November 2003. Table 1 presents
he baseline characteristics and procedural outcomes for this
atient population. A second overlapping stent was im-
lanted in two patients to treat a dissection following
mplantation of the first stent.
linical outcome. Table 2 provides an overview of the
ACCE at one and nine months. There was no subacute
hrombosis or MACCE in the first month after implanta-
ion. During the first nine months, MACCE occurred in a
atient with insulin-dependent diabetes with diabetic ne-
hropathy. This patient (#12) was admitted with a non–
T-segment elevation MI (maximum creatinine kinase level
as 524 U/l) at six months after the index procedure and
nderwent recatheterization that demonstrated focal in-
tent restenosis with TIMI flow grade 3 and no visible
ontrast detect, which could have been caused by stent
hrombosis. No MACCE was reported in other patients.
ix-month angiographic and IVUS results in stented
egment. Scheduled coronary angiography at six months
as performed in 15 patients (93.8%). The patient who
efused angiography was asymptomatic. At six months,
able 1. Baseline Characteristics and Procedural Outcomes,
atients (n  16)
en 11 (69%)
ge (yrs) 68  10
iabetes 5 (31%)
ypertension 12 (75%)
ypercholesterolemia 12 (75%)
amily history 6 (38%)
urrent smoking 4 (25%)
nstable angina 8 (50%)
arget coronary artery
LAD 8 (50%)
RCA 5 (31%)
LCX 3 (19%)
esion type
A 8 (50%)
B1 6 (38%)
B2 2 (13%)
C 0 (0%)
ngiographic features
Lesion length (mm) 10.6  4.0
Reference vessel diameter (mm) 2.63  0.30
Minimal luminal diameter (mm) 0.95  0.33
Diameter stenosis (%) 63.7  11.9
rocedural outcomes
Mean stent diameter (mm) 3.3  0.3
Mean stent length (mm) 18.4  6.4
Overlapping stenting 2 (13%)
Post dilation 8 (50%)
Direct stenting 2 (13%)
Use of glycoprotein IIb/IIIa inhibitor 3 (19%)
Angiographic success 16 (100%)
AD  left anterior descending; LCX  left circumflex; RCA  right coronary
rtery.ean late luminal loss was 0.63 mm on quantitative
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May 17, 2005:1574–9 First Human Experience of EPC Capture Stentoronary angiography and percent stent volume obstruction
as 27.2% on IVUS (Table 3). Binary restenosis occurred in
wo patients (13.3%). Restenosis was focal in one patient
nd diffuse in the other. In the case of the patient with
iffuse restenosis (case #4), the patient had no symptoms
nd a percent diameter stenosis was 58% at six months. This
atient did not undergo repeat revascularization. Focal
estenosis occurred in an insulin-dependent patient (case
12). This patient was subsequently treated with directional
oronary atherectomy and implantation of a paclitaxel-
luting stent. Intravascular ultrasound analysis revealed
ncomplete stent apposition in one patient (6.3%), which
ad resolved at six months. Furthermore, no late-acquired
able 2. Clinical Outcomes at 1 Month and 9 Months
eath
Within 1 month 0%
9 months 0%
troke
Within 1 month 0%
9 months 0%
-wave MI
Within 1 month 0%
9 months 0%
on–Q-wave MI
Within 1 month 0%
9 months 6.3% (1/16)
VR
Within 1 month 0%
9 months 6.3% (1/16)
ACCE
Within 1 month 0%
9 months 6.3% (1/16)
tent thrombosis
Within 1 month 0%
9 months 0%
ACCE  major adverse cardiac and cerebrovascular events; MI  myocardial
nfarction; TVR  target vessel revascularization.
able 3. Serial Quantitative Analysis of the Stented Segment by
CA and IVUS (n  15)
Post
6-Month
Follow-Up
p
Value
CA
RVD (mm) 2.71  0.31 2.69  0.32 0.738
MLD (mm) 2.47  0.29 1.84  0.56 0.0004
%DS 8.5  3.4 32.1  16.7 0.0001
Stent thrombosis (%) 0%
Late loss (mm) 0.63  0.52
Loss index 0.45  0.39
Binary restenosis 13.3% (2/15)
VUS
Vessel volume (mm3) 336.5  86.7 339.9  88.9 0.583
Stent volume (mm3) 173.5  44.9 175.0  42.6 0.715
Plaque behind stent
volume (mm3)
163.0  56.6 165.0  62.9 0.371
Neointima volume (mm3) 51.7  47.8
% in-stent obstruction 27.2  20.9
In-stent malapposition 6.7% (1/15) 0%
S  diameter stenosis; IVUS  intravascular ultrasound; MLD  mean luminalc
iameter; QCA  quantitative coronary angiography; RVD  revascularized vessel
iameter.ncomplete stent apposition was observed for the entire
atient population.
istology of the atherectomy specimen. Histologic anal-
sis showed tissue consisting of a mixture of myxoid and
brous material with variable cell density. Some of the
brous pieces showed a paucity of cells. The myxoid
ragments consisted of smooth muscle cells (SMCs) within
ariable amounts of proteoglycan (Figs. 2A to 2C). Some
hrombus remnants were seen and assessed to be several
ays old (Figs. 2D and 2E, no SMCs, only some nuclei),
resumably related to the small MI. The atherectomy
pecimens included metal stent fragments. That indicates
hat the plaques behind the stent struts were included in the
pecimens. There were large areas of calcification in both
he fibrous and myxoid tissue (Fig. 2F), presumably old
laque, as these were also observed with IVUS. Immuno-
ytochemistry (Figs. 2C and 2E) shows that most cells were
MC-alpha-actin positive. Mib-1 (proliferation), Mac387
macrophages), and CD34 were negative. There were only a
ew CD45-positive cells (leukocytes).
AMA test results. The HAMA testing was conducted
n a subset of the population (last four consecutive patients).
positive assay due to the treatment with the study device
as not observed in these patients.
ISCUSSION
his study is the first clinical experience with implantation
f a bioengineered stent. The results of the HEALING-
IM registry show that the EPC capture stent is safe and
easible: with no stent thrombosis (30 days or 6 months),
nd MACCE occurred in only one patient (6.3%), despite
nly 30 days of clopidogrel therapy.
This clinical registry was preceded by several experimen-
al studies. In an in vivo study, at 1 h after deployment the
PC capture stent showed a 90% cell coverage, while the
are stainless steel stents were almost completely devoid of
ells. Histologic analysis at 31 days showed that percent area
uminal stenosis was significantly reduced with the EPC
apture stents compared with stainless steel stents (15.49 
.54% vs. 23.96  7.70%, p  0.01) (9).
These preclinical and preliminary clinical results have to
e interpreted carefully, considering the recent emergence of
ew technologies such as drug-eluting stents. Drug-eluting
tents inhibit the inflammatory and proliferative process of
he normal healing response, including the formation of a
onfluent endothelial layer on the stent (3). The EPC
apture stents induce the rapid establishment of a functional
ndothelial layer early in the healing response. In this
egistry, the atherectomy specimen indicated a well-healed
rtery with minimal inflammation.
Of note, the neointimal hyperplasia in the EPC capture
oating stents was not significantly reduced when compared
ith the usual late loss seen after conventional bare metal
tent implantation. It has been argued that EPC capture
oating covers only the stent struts, and theoretically no
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First Human Experience of EPC Capture Stent May 17, 2005:1574–9arly functional endothelial lining can be expected in the
nterstrut space, although the interstrut area in the animal
odel (healthy coronary artery undergoing direct stenting)
as covered with functional endothelium within 48 h; this
ituation differs substantially from a human pathologic
therosclerosis vessel after balloon injury. In addition, the
ioactivity of these prototype EPC capture stents used in
EALING-FIM registry was unstable and was easily
educed by sterilization with gamma irradiation. It was
ubsequently discovered through the use of a bioassay that
amma irradiation lessened the immunoaffinity of EPC
apture prototype stents used in this trial. Therefore, it is
ikely that the reduced bioactivity of EPC capture stents in
he HEALING-FIM registry may not have been enough to
nhibit neointimal hyperplasia after stent implantation.
The technology behind the creation of an EPC affinity
urface is achieved by attaching murine monoclonal antihu-
an CD 34 antibodies to the stent. An immunoreaction
gainst the murine monoclonal antibody may occur in
atients who have human ant-murine antibody (HAMA).
n addition, production of HAMA may result in the
igure 2. Overview (A) and details (left: B, C; mid: D, E; right: F) of the a
hows a mixture of myxoid (B, C) and fibrous material (F) consisting of sm
ragments contained thrombus remnants (Th) (D, E) and calcificatio
mmunocytochemistry for smooth muscle cell-specific alpha actin.eutralization of the EPC capture surface. In this registry,ncreased HAMA levels were not observed in the four
atients who underwent serial HAMA testing, and no
atients exhibited systemic symptoms of immunoreaction.
his safety issue was in agreement with other trials, evalu-
ting immunologic treatment using murine antibody for
varian cancer (10).
Because of the small sample size and single-center en-
able 4. Evolution of Endothelial Progenitor Cell Capture
tent: Improvement From HEALING-FIM (H1) to
EALING II (H2)
Device
H1 - Wet, hand-crimped
H2 - Dry, premounted
Stability
H1 - Wet; supplied in sodium azide preservative; required rinsing
before use
H2 - Dry, formulated to preserve antibody structure & activity
Sterilization
H1 - Gamma irradiation; 15 to 25 kGy
H2 - Gamma irradiation; 15 kGy
Bioactivity
H1 - Significant reduction in activity with sterilization
ctomy specimen obtained six months following stent placement. Histology
muscle cells (C, E) within variable amounts of extracellular matrix. Some
a) (F). A  elastin stain; B, D, F hematoxylin eosin; C, E there
oothH2 - Stable with sterilization
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May 17, 2005:1574–9 First Human Experience of EPC Capture Stentollment, the present study did not fully evaluate the efficacy
f this device. However, further developments in this
echnology, such a providing a dry stent premounted on a
elivery system and maintaining good activity post-
terilization, are currently being evaluated in the
EALING-II registry (Table 4). The technology for pre-
erving antibody structure and bioactivity has advanced,
esulting in a higher capture of EPCs (Fig. 3). As a result of
hese improvements, further clinical investigation of this
echnology is warranted to evaluate the efficacy of this device
or the treatment of coronary artery disease.
onclusions. The present study demonstrates that the
igure 3. Endothelial progenitor cell capture stent bioactivity (in vitro).
he cell-binding activity of the HEALING-FIM and HEALING-II
tents was compared with negative controls (bare stents). In the bioassay,
tents were exposed to a suspension of human CD34 cells (kg-1a cells,
merican Type Culture Collection) for 1 h with agitation. Excess cells are
emoved and bound cells are tagged with a fluorescent nuclear stain (DAPI,
=6-diamidino-2-phenylindole). After rinsing, the stents were placed in a
icroplate for analysis in a fluorescent plate reader. The number of cells
ound was calculated by interpolation from standard curve on the same
late.PC capture stent is safe and feasible. Further study andevelopment of this promising technology are needed to
onfirm the clinical efficacy of this bio-engineered stent.
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horaxcenter, Bd 406, Erasmus Medical Center, Dr. Molewater-
lein 40, 3015 GD Rotterdam, the Netherlands. E-mail: p.w.j.c.
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